This is an institutional cohort study. Patients confirmed with spinocerebellar ataxia (SCA)
and taking or planning to take Nilotinib (Tasigna®) are enrolled in this study. The daily
dose of Nilotinib is 150mg-300mg and the patients will be followed up at 1, 3, 6, and 12
months. Rating scale for Friedreich's ataxia I and II and Barthel index are used as general
function and daily living performance index. Scale for assessment and rating of ataxia (SARA)
are used as an objective measure of cerebellar function. Adverse drug reactions are evaluated
based on CTCAE version 4.0.